The Latest Analyst Ratings For Edwards Lifesciences
Edwards Lifesciences Analyst Ratings
Edwards Lifesciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)
Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept
Edwards Lifesciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)
Buy Rating on Edwards Lifesciences Amid Expanding TAVR Market and Positive SMART Trial Outlook
Edwards Lifesciences Stock Upgraded to Buy, PT Lifted to $105
Edwards Lifesciences Analyst Ratings
Buy Rating on Edwards Lifesciences Amidst Strong TAVR Business and Promising TMTT Expansion
Edwards Lifesciences (EW) Gets a Buy From Wells Fargo
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Edwards Lifesciences (EW) and Coya Therapeutics, Inc. (COYA)
Wells Fargo Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Barclays Remains a Buy on Edwards Lifesciences (EW)
Buy Rating Affirmed for Edwards Lifesciences on Evoque TTVR System's FDA Approval and Promising Trial Results
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating
Mizuho Maintains Buy on Edwards Lifesciences, Raises Price Target to $95
Edwards Lifesciences Analyst Ratings
No Data